Article

Take the omni-focal approach

An omni-focal approach, combining an aspheric prebyopic treatment with a hyperopic ablation, looks promising as a method for improving near vision in hyperopes with presbyopia.

An omni-focal approach, combining an aspheric prebyopic treatment with a hyperopic ablation, looks promising as a method for improving near vision in hyperopes with presbyopia, according to Efekan Coskunseven from the Dunya Eye Hospital, Istanbul, Turkey.

Dr Coskunseven explained that the wavefront-guided treatment is dependent on pupil size and is designed to correct refractive errors, in addition to higher order aberrations. The aspheric ablation algorithm uses a combination of variable spot scanning (VSS), variable repetition rate (VRR), WaveScan aberrometry with Hartmann-Shack and Fourier technology and iris recognition to improve the accuracy of the ablation and to ensure correct placement on the cornea. All treatments were performed using the AMO/VISX Star S4 CustomVue excimer laser.

The global clinical results, so far, suggest that 100% of eyes treated with this system have achieved simultaneous binocular vision of 20/25 distance and J3 near vision by one year follow-up, with very little decline in contrast sensitivity. Dr Coskunseven, in his own case series, found that 90% of eyes achieved a near vision of J3 or better at six months.

Although some patients do experience a decline in distance vision, the loss is considered negligible. Overall, however, the treatment approach is showing promise and longer-term follow-up is required to assess the visual changes more thoroughly.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.